Sam Shimamoto, MD
Allergy & Immunology · Gilbert, AZNPI 1073587382
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.1%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Genentech USA, Inc. accounts for 73.4% of it on its own, with 36 other manufacturers making up the rest. Reporting peaked in 2019 at $12,590 and has fallen 80.6% since, to $2,437 in 2025.
Across 334 payments — averaging $107.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$26K
- Regeneron$3K
- AstraZeneca$664
- Regeneron Healthcare Solutions, Inc.$650
- Takeda Pharmaceuticals U.S.A., Inc.$591
- GSK$484
- plus $4K from 31 others
Across 19 payments — averaging $3872.82 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$62K
- Regeneron$7K
- Arcutis Biotherapeutics, Inc.$4K
What the payments were for
- Consulting fees$6,38018%
- Speaking & faculty fees$21,29059%
- Travel & lodging$1,0543%
- Food & beverage$6,97119%
- Education$3011%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 40 | $26,414 |
| Regeneron | 5 | $3,103 |
| AstraZeneca | 16 | $664 |
| Regeneron Healthcare Solutions, Inc. | 30 | $650 |
| Takeda Pharmaceuticals U.S.A., Inc. | 32 | $591 |
| GSK | 27 | $484 |
| Amgen(2 entities) | 18 | $479 |
| Sanofi | 15 | $451 |
| Novartis | 16 | $315 |
| Pharming Healthcare, Inc. | 12 | $284 |
| Genentech, Inc. | 4 | $253 |
| CSL Behring | 9 | $233 |
| Grifols USA, LLC | 13 | $224 |
| ADMA Biomanufacturing LLC | 17 | $210 |
| Pfizer | 10 | $182 |
| LEO Pharma Inc. | 8 | $161 |
| Sanofi-aventis U.S. LLC | 2 | $160 |
| Biocryst US Sales Co., LLC | 7 | $159 |
| Kaleo, Inc. | 6 | $141 |
| Incyte Corporation | 7 | $131 |
| AbbVie | 4 | $89 |
| Optinose US, Inc. | 4 | $71 |
| Blueprint Medicines Corporation | 2 | $64 |
| Organon | 7 | $61 |
| Greer Laboratories, Inc. | 2 | $58 |
| GC Biopharma USA, Inc. | 3 | $56 |
| Lilly USA, LLC | 2 | $48 |
| Kedrion Biopharma, Inc. | 2 | $41 |
| Hikma Pharmaceuticals USA | 2 | $39 |
| Mylan Specialty L.p. | 1 | $36 |
| Shire North American Group Inc | 2 | $30 |
| Covis Pharma GmbH | 1 | $30 |
| Aimmune Therapeutics, Inc. | 1 | $23 |
| Bio Products Laboratory USA, Inc. | 4 | $23 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Merck | 1 | $13 |
| Cycle Pharmaceuticals Inc | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$35,996 in reported general payments places this provider in the 85th percentile of 90 allergy & immunology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 89 | $484,881 |
| Dupixent SyringeDupilumab | 68 | $290,596 |
| XolairOmalizumab | 42 | $125,857 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 11 | $98,236 |
| CutaquigImmun Glob G(Igg)-Hipp/Maltose | 11 | $93,693 |
| TezspireTezepelumab-Ekko | 13 | $53,281 |
| Dupixent PenDupilumab | 14 | $51,196 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 52 | $46,108 |
| Breo ElliptaFluticasone/Vilanterol | 48 | $30,273 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 32 | $21,803 |
| Epinephrine | 86 | $15,593 |
| SymbicortBudesonide/Formoterol Fumarate | 33 | $11,269 |
| RyaltrisOlopatadine Hcl/Mometasone | 28 | $10,464 |
| Spiriva RespimatTiotropium Bromide | 16 | $9,412 |
| BreynaBudesonide/Formoterol Fumarate | 26 | $6,111 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringHizentra | $233 | $484,88189 claims |
| Genentech, Inc.Xolair | $253 | $125,85742 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $591 | $98,23611 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $664 | $86,35378 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $484 | $80,770116 claims |
| Hikma Pharmaceuticals USAEpinephrine, Ryaltris | $39 | $26,057114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 90 allergy & immunology providers in Arizona.
Other allergy & immunology in Gilbert
- Neal JainGilbert$388K
- Earl LabovitzGilbert$2K
- Doina LapusanGilbert$1K
- Michael ManningScottsdale$1.1M
- Jennifer HillScottsdale$335K
- Jean NelsonScottsdale$183K
- Kiranjit KhalsaScottsdale$124K
- Keith SaccoPhoenix$118K
- Jacob MadduxSurprise$87K
- Tara CarrTucson$76K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.